- Home
- By Diseases
- Infectious Ophthalmic Diseases
- Gonococcal Conjunctivitis (GC)
Gonococcal conjunctivitis (GC) is an eye condition resulting from a Gram-negative diplococcus bacterium, Neisseria gonorrhoeae. As an experienced research service provider, Protheragen offers comprehensive services for developing diagnostics and therapeutics for gonococcal conjunctivitis.
Gonococcal conjunctivitis (GC) is an acute ocular infection of Neisseria gonorrhoeae. Its manifestations include acute conjunctival inflammation with copious mucopurulent discharge, eyelid swelling, chemosis, and severe pain. Gonococcal conjunctivitis is described in individuals of all ages, but the most prevalent cases are in newborns and older sexually active individuals. For newborns, Gonococcal conjunctivitis is something an infected mother bestows on her child during birth, while in adults, it is caused by touching the genitals and then the eyes or vice versa. Untreated gonococcal conjunctivitis is associated with a rapid course of severe complications, which include keratitis, corneal ulceration, perforation, endophthalmitis, and blindness.
Microbiological Culture
The gold standard diagnostic procedure for gonococcal conjunctivitis is the use of microbiological cultures. For this purpose, conjunctival swabs are taken, placed on selective media like chocolate agar, and incubated to cultivate Neisseria gonorrhoeae. Initially, the presence of gram-negative diplococci may be detected through a Gram stain. Systematic approaches based upon cultures have better specificity and enable testing of the sensitivities to antibiotics, which is important for specifying therapeutic options.
Polymerase Chain Reaction (PCR)
This method of PCR makes it possible to swiftly and precisely diagnose Neisseria gonorrhoeae by amplifying its DNA from eye samples. Moreover, PCR can identify the bacterium's presence in samples that would otherwise be deemed non-cultivable due to minimal bacterial count or slow bacterial growth. With multiplex PCR, other eye infectious agents like Chlamydia trachomatis can also be detected which improves the accuracy of the diagnosis significantly.
Rapid Antigen Detection Tests
The diagnosis of eye infections caused by Neisseria gonorrhoeae can be done promptly with rapid antigen detection tests that detect specific antigens of the bacterium. The results can be received within minutes, which aids in swift clinical decision-making. However, the tests have a lower sensitivity, specificity, and overall accuracy than PCR or culture methods. Regardless of these disadvantages, rapid antigen tests are appropriate in low resource areas where answers are required quickly.
Systemic Antibiotics
The therapeutics of GC primarily involves the use of systemic antibiotics with the aim of eradicating the causative bacteria. One of the most used options is ceftriaxone, which is effective against Neisseria gonorrhoeae because it is a third generation cephalosporin. It can be given intravenously or intramuscularly which provides broad coverage and fast bactericidal capabilities. Azithromycin is co-administered with ceftriaxone so that possible co-infections with Chlamydia trachomatis are also treated and the development of resistance is minimized.
Topical Antibiotics
Topical antibiotics are essential for the adequate control of local ocular complications and symptoms. The use of fortified tobramycin and cephalosporin eye drops is frequent in order to attain high local concentrations of antibiotics which control inflammation and stave off corneal complications. Severe ocular infections can be treated topically with ciprofloxacin and ofloxacin, which are broad-spectrum fluoroquinolone antibiotics. Such therapy achieves the desired result of effective local treatment without systemically affecting the organism.
Protheragen offers comprehensive services to support the development of novel diagnostics and therapeutics for gonococcal conjunctivitis. These services encompass the entire preclinical development pathway, from initial target identification to in vivo efficacy studies. Protheragen's expertise in microbiology, immunology, and pharmacology enables the company to deliver high-quality data and accelerate the development process.
Protheragen understands that each drug and diagnostic development program is unique. Therefore, our company offers customized services to meet specific client requirements. If you are interested in our services, please feel free to contact us.
References